Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate

Authors

  • Aghasadeghi, MR Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
  • Asgarhalvaee , F Department of Microbiology, Pharmacotical Science Branch, Islamic Azad University, Tehran, Iran.
  • Aslani , MM Microbiology Research Center (MRC) Pasteur Institute of Iran, Tehran, Iran./ Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran.
  • Ghahari , SMM Department of Immunology, School of Medicine, Mazandaran University of Medical sciences, Sari, Iran.
  • Hekmat , S Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
  • Mahdavi , M Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
  • Sadat, SM Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
  • Shafiee Ardestani , M Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences. Tehran, Iran.
  • Shahbazi, S Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
  • Siadat , SD Microbiology Research Center (MRC) Pasteur Institute of Iran, Tehran, Iran./ Department of Mycobacteriology and pulmonary research, Pasteur Institute of Iran, Tehran, Iran.
  • Tohidi, F Department of Microbiology, Science and Research Branch, Islamic Azad University, Fars, Iran.
Abstract:

Introduction: Hepatitis C virus (HCV) is one of the most serious causes of cirrhosis, liver cancer and ultimately death, worldwide. The new direct-acting drugs are not accessible for many patients around the world and progress toward new therapeutic and anaphylactic vaccines design has not been fast enough. This study was aimed to prepare and assess a recombinant fusion protein core-NS3 (rC-N) of HCV with the accompaniment of d,l-polylactide-co-glycolide nanoparticles (PLGA NPs)  as a nano-conjugated vaccine candidate. Methods: The rC-N protein containing the first domain of core and middle region of NS3 (residues 1095-1384) was loaded into PLGA NPs (rC-N/PLGA NPs) by NHS and DDC (equimolar: 0.5 mM) as conjugating agents. The morphology and average of surface roughness (Ra) of PLGA NPs and rC-N/PLGA NPs were demonstrated by atomic force microscope (AFM). The particle sizes, polydispersity index (PDI) and zeta potential were measured by Zetasizer. Results: The morphology of the nanoparticles was spherical and their surface Ra was measured to be 7.630 nm for PLGA NPs and 15.72 nm for rC-N/PLGA NPs. The average size (160.4 nm), zeta potential (-37.6 mV) and PDI (0.227) were also obtained for rC-N/ PLGA NPs. Conclusion: The surface Ra value of rC-N/PLGA NPs (15.72 nm) which was twice more than PLGA NPs (7.630 nm) confirmed a successful conjugation. The stability of nanoparticles behavior in the colloid was confirmed by the absolute value of zeta potential (|-37.6|= 37.6 mV) of rC-N/PLGA NPs. The spherical morphology, average size < 200, an absolute value of zeta potential > 30 mV, PDI < 0.5 were confirmatory indications that rC-N/PLGA NPs could be considered as vaccine candidate. The rC-N/PLGA NPs construct should be further evaluated via in-vivo challenges and demonstration of targeted delivery to the antigen presenting cells.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Cloning, Expression and Characterization of Recombinant Exotoxin A-Flagellin Fusion Protein as a New Vaccine Candidate against Pseudomonas aeruginosa Infections

Background: Infections due to Pseudomonas aeruginosa are among the leading causes of morbidity and mortality in patients who suffer from impaired immune responses and chronic diseases such as cystic fibrosis. At present, aggressive antibiotic therapy is the only choice for management of P. aeruginosa infections, but emergence of highly resistant strains necessitated the development of novel alt...

full text

construction and preparation of three recombinant adenoviruses expressing truncated ns3 and core genes of hepatitis c virus for vaccine purposes

background in spite of dozens of clinical trials to establish effective therapeutic and/or preventive vaccine to resolve hcv infection, no real vaccine has been proved to date. genetic vaccines based on replication-defective adenoviruses have proved to elicit strong and long lasting t-cell responses against a number of viral antigens and are even currently being used for vaccine trials in human...

full text

Construction of an Expression Vector Containing a Novel Fusion Sequence from Middle Region of NS3 and Truncated Core Genes of Hepatitis C Virus

Background and Aims: DNA constructs containing HCV antigens have become one of the vaccine candidates for induction of anti-HCV cellular and humoral immunity. In this study, we constructed a novel expressing vector harboring a fusion sequence derived from an overlapping fragment in the middle of NS3 and a truncated core fragment to avoid troubles reported to be associated with full gene express...

full text

CpG Motif as an Adjuvant in Immunization of a Recombinant Plasmid Encoding Hepatitis C Virus Core Protein

full text

Construction and Preparation of Three Recombinant Adenoviruses Expressing Truncated NS3 and Core Genes of Hepatitis C Virus for Vaccine Purposes

BACKGROUND In spite of dozens of clinical trials to establish effective therapeutic and/or preventive vaccine to resolve HCV infection, no real vaccine has been proved to date. Genetic vaccines based on replication-defective adenoviruses have proved to elicit strong and long lasting T-cell responses against a number of viral antigens and are even currently being used for vaccine trials in human...

full text

Cloning and expression of hepatitis E virus ORF2 as a vaccine candidate

Introduction: Hepatitis E virus (HEV) is a fecal-oral transmitting virus which causes a chronic liver disease. ORF2 is an immunogen capsid protein of HEV that has been proposed to be used for Hepatitis E vaccine design. It is a 660-amino acid protein which includes an immunogenic region (residues 112-607). This protein has been expressed in complete and truncated forms, using different expressi...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue 1

pages  13- 18

publication date 2017-05

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023